| Company/Division name | Rubius Therapeutics |
| Parent company | Rubius Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2018 |
| Capital investment ($): | 155 |
| City reshored to: | Smithfield |
| State(s) reshored to: | RI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | stem cells and stimulate them into red blood cells |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Manufacturing/engineering joint innovation (R&D), Under-utilized capacity |
| Government Incentive dollar amount: | 2.75 million in tax credits |
